106 related articles for article (PubMed ID: 38310574)
1. Astragaloside IV Overcomes Anlotinib Resistance in Non-small Cell Lung Cancer through miR-181a-3p/UPR-ERAD Axis.
Wang L; Sun T; Yang X; Wen Z; Sun Y; Liu H
Curr Comput Aided Drug Des; 2024 Jan; ():. PubMed ID: 38310574
[TBL] [Abstract][Full Text] [Related]
2. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
[TBL] [Abstract][Full Text] [Related]
3. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A.
Gu G; Hu C; Hui K; Zhang H; Chen T; Zhang X; Jiang X
Int J Nanomedicine; 2021; 16():6329-6343. PubMed ID: 34556984
[TBL] [Abstract][Full Text] [Related]
4. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.
Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ
Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822
[TBL] [Abstract][Full Text] [Related]
5. MiR-181a reduces radiosensitivity of non-small-cell lung cancer via inhibiting PTEN.
Chen Y; Liao W; Yuan A; Xu H; Yuan R; Cao J
Panminerva Med; 2022 Sep; 64(3):374-383. PubMed ID: 32506887
[TBL] [Abstract][Full Text] [Related]
6. RNA editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non-small cell lung cancer cells to anlotinib by regulating CX3CR1-fractalkine expression.
Wu M; Jin M; Cao X; Qian K; Zhao L
Drug Dev Res; 2022 Apr; 83(2):328-338. PubMed ID: 34319598
[TBL] [Abstract][Full Text] [Related]
7. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
8. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
9. SNHG7 Contributes to the Progression of Non-Small-Cell Lung Cancer via the SNHG7/miR-181a-5p/E2F7 Axis.
Wang L; Zhang L; Wang L
Cancer Manag Res; 2020; 12():3211-3222. PubMed ID: 32440218
[TBL] [Abstract][Full Text] [Related]
10. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
Ping W; Gao Y; Fan X; Li W; Deng Y; Fu X
Biochem Biophys Res Commun; 2018 Jan; 495(4):2482-2489. PubMed ID: 29269300
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA SNHG7 Accelerates Proliferation, Migration and Invasion of Non-Small Cell Lung Cancer Cells by Suppressing miR-181a-5p Through AKT/mTOR Signaling Pathway.
Li L; Ye D; Liu L; Li X; Liu J; Su S; Lu W; Yu Z
Cancer Manag Res; 2020; 12():8303-8312. PubMed ID: 32982425
[TBL] [Abstract][Full Text] [Related]
12. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
14. Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment.
Wei L; Jiang J
Bioengineered; 2021 Dec; 12(1):2499-2510. PubMed ID: 34107856
[TBL] [Abstract][Full Text] [Related]
15. Targeting Oncogenic miR-181a-2-3p Inhibits Growth and Suppresses Cisplatin Resistance of Gastric Cancer.
Jin L; Ma X; Zhang N; Zhang Q; Chen X; Zhang Z; Ding G; Yu H
Cancer Manag Res; 2021; 13():8599-8609. PubMed ID: 34815714
[TBL] [Abstract][Full Text] [Related]
16. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
Liu Y; Zhang Y; Li Q; Xu R; Huang N
Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
[TBL] [Abstract][Full Text] [Related]
17. miR-199a-3p/5p regulate tumorgenesis via targeting Rheb in non-small cell lung cancer.
Liu X; Wang X; Chai B; Wu Z; Gu Z; Zou H; Zhang H; Li Y; Sun Q; Fang W; Ma Z
Int J Biol Sci; 2022; 18(10):4187-4202. PubMed ID: 35844793
[TBL] [Abstract][Full Text] [Related]
18. MNK/eIF4E inhibition overcomes anlotinib resistance in non-small cell lung cancer.
Zhang Q; Li H; Li Q; Hu Q; Liu B
Fundam Clin Pharmacol; 2023 Apr; 37(2):245-252. PubMed ID: 36355605
[TBL] [Abstract][Full Text] [Related]
19. MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1.
Shi Q; Zhou Z; Ye N; Chen Q; Zheng X; Fang M
Cancer Biomark; 2017 Dec; 20(4):539-546. PubMed ID: 28946554
[TBL] [Abstract][Full Text] [Related]
20. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
